RCKT Stock News & Catalysts – Rocket Pharmaceuticals

FEATURED

Rocket Pharmaceuticals to Participate in Chardan’s 10th Annual Healthcare Conference

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders,

Summary

Oct 15, 2026, 7:00 AM ·Business Wire

RECENT

Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar

Oct 7, 2026, 9:36 AM ·Business Wire

Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and life-threatening diseases, focused on inherited cardiovascular disorders,

Oct 6, 2026, 4:12 PM ·Business Wire

Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease

FDA confirms pivotal efficacy population of 12 patients, including the first three treated under the modified protocol FDA review of initial safety data supports continued enrollment and dosing under modified

Sep 15, 2026, 7:00 AM ·Business Wire

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare and devastating diseases, focused on inherited cardiovascular disorders, today

Sep 3, 2026, 7:00 AM ·Business Wire

Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress

All three initial patients treated with RP-A501 under the modified pivotal Phase 2 protocol completed the protocol-defined safety observation period; no thrombotic microangiopathy, capillary leak syndrome, or other

Aug 10, 2026, 4:00 PM ·Business Wire

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease

Initial three patients were treated safely; RP-A501 was well-tolerated with no TMA or capillary leak syndrome observed Rocket is actively engaging with the FDA to align on the path to pivotal trial completion;

Aug 3, 2026, 7:00 AM ·Business Wire

Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced the

Jun 12, 2026, 7:00 AM ·Business Wire

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

May 28, 2026, 7:00 AM ·Business Wire

Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress

Pivotal Phase 2 trial of RP-A501 for Danon disease progressing with dosing reinitiated First patient dosing in Phase 1 study of RP-A701 for BAG3-related dilated cardiomyopathy anticipated in

May 7, 2026, 4:00 PM ·Business Wire

Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher

PRV monetization provides $180 million in non-dilutive capital to support cardiovascular pipeline Cash runway extended into the second quarter of 2028 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated,

Apr 28, 2026, 7:00 AM ·Business Wire

Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)

First FDA-approved gene therapy for children with severe LAD-I due to biallelic variants in ITGB2 Severe LAD-I is an ultra-rare, life-threatening pediatric genetic immunodeficiency characterized by recurrent

Mar 27, 2026, 7:00 AM ·Business Wire

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress

Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026 KRESLADI™ for severe LAD-I on track for March 28, 2026 PDUFA date Dosing of first patient in Phase 1 study of RP-A701 for BAG3-related

Feb 26, 2026, 4:00 PM ·Business Wire

Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that the

Feb 23, 2026, 7:00 AM ·Business Wire

Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Jan 5, 2026, 7:00 AM ·Business Wire

Rocket Pharmaceuticals, Inc. RCKT · News